Hutchens Investment Management Inc Lowers stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Hutchens Investment Management Inc reduced its stake in Becton Dickinson and Co by 3.54% during the most recent quarter end. The investment management company now holds a total of 15,676 shares of Becton Dickinson and Co which is valued at $2,727,310 after selling 575 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Becton Dickinson and Co makes up approximately 2.51% of Hutchens Investment Management Inc’s portfolio.

Other Hedge Funds, Including , Columbia Partners L L C Investment Management boosted its stake in BDX in the latest quarter, The investment management firm added 322 additional shares and now holds a total of 12,600 shares of Becton Dickinson and Co which is valued at $2,192,148. Becton Dickinson and Co makes up approx 0.16% of Columbia Partners L L C Investment Management’s portfolio.Coldstream Capital Management Inc boosted its stake in BDX in the latest quarter, The investment management firm added 9 additional shares and now holds a total of 1,495 shares of Becton Dickinson and Co which is valued at $264,181. Becton Dickinson and Co makes up approx 0.04% of Coldstream Capital Management Inc’s portfolio.Boston Family Office boosted its stake in BDX in the latest quarter, The investment management firm added 960 additional shares and now holds a total of 8,564 shares of Becton Dickinson and Co which is valued at $1,487,824. Becton Dickinson and Co makes up approx 0.19% of Boston Family Office’s portfolio.

Becton Dickinson and Co opened for trading at $173.2 and hit $174 on the upside on Friday, eventually ending the session at $173.85, with a gain of 0.09% or 0.15 points. The heightened volatility saw the trading volume jump to 7,13,720 shares. Company has a market cap of $37,017 M.

On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.

Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *